Pulmatrix (PULM) News Today $7.70 +0.03 (+0.39%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$7.71 +0.01 (+0.12%) As of 01/31/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Pulmatrix (NASDAQ:PULM) Shares Pass Above 50 Day Moving Average - Time to Sell?January 30 at 3:51 AM | americanbankingnews.comCullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic PainJanuary 23, 2025 | finance.yahoo.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. – PULMNovember 14, 2024 | globenewswire.comPulmatrix Inc.: Pulmatrix and Cullgen Announce Proposed MergerNovember 14, 2024 | finanznachrichten.dePulmatrix Shares Surge on Merger with CullgenNovember 14, 2024 | marketwatch.comPulmatrix Shares Hit 52-Week High After News of Merger DealNovember 14, 2024 | marketwatch.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of ShareholdersNovember 14, 2024 | globenewswire.comShareholder Alert: Ademi LLP investigates whether Pulmatrix, Inc. is obtaining a Fair Price for its Public ShareholdersNovember 13, 2024 | businesswire.comPulmatrix and Cullgen Announce Proposed MergerNovember 13, 2024 | prnewswire.comPulmatrix Third Quarter 2024 Earnings: US$0.71 loss per share (vs US$1.03 loss in 3Q 2023)November 11, 2024 | finance.yahoo.comPulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 8, 2024 | prnewswire.comPulmatrix Second Quarter 2024 Earnings: US$1.59 loss per share (vs US$1.05 loss in 2Q 2023)August 15, 2024 | finance.yahoo.comPulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 13, 2024 | prnewswire.comPulmatrix IncJuly 30, 2024 | money.usnews.comMNKD Jul 2024 6.000 call (MNKD240726C00006000)July 20, 2024 | finance.yahoo.comMNKD Jul 2024 5.000 put (MNKD240726P00005000)July 20, 2024 | finance.yahoo.comPulmatrix, Inc. (PULM)July 19, 2024 | finance.yahoo.comPulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind CorporationMay 29, 2024 | prnewswire.comTezepelumab Shows Potential for COPD, Negative Trial NotwithstandingMay 22, 2024 | msn.comPulmatrix Inc.: Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)May 15, 2024 | finanznachrichten.dePulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)May 15, 2024 | prnewswire.comPulmatrix First Quarter 2024 Earnings: EPS: US$0.23 (vs US$1.22 loss in 1Q 2023)May 12, 2024 | finance.yahoo.comPulmatrix Inc.: Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | finanznachrichten.dePULM Stock Earnings: Pulmatrix Reported Results for Q1 2024May 10, 2024 | investorplace.comPulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | prnewswire.comPULM Stock Earnings: Pulmatrix Beats EPS, Beats Revenue for Q4 2023March 28, 2024 | investorplace.comPulmatrix Inc.: Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate UpdateMarch 28, 2024 | finanznachrichten.dePulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate UpdateMarch 28, 2024 | prnewswire.comCipla Ltd CIPLAFebruary 15, 2024 | morningstar.comFive things: Boston State of the City, high business costs, biotech shutdowns and Boston Calling headlinersJanuary 10, 2024 | bizjournals.comPulmatrix shuts down study, explores saleJanuary 9, 2024 | bizjournals.comPulmatrix To Stop PUR1900 Phase 2B Study Patient Enrollment And Closing The StudyJanuary 8, 2024 | nasdaq.comPulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic AlternativesJanuary 8, 2024 | marketwatch.comPulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic AlternativesJanuary 8, 2024 | finance.yahoo.comStocks in news: Titan, Marico, Bajaj Auto, Adani Wilmar, Tata SteelJanuary 8, 2024 | msn.comStock Market Today: Dr Reddy's, Titan, And Reliance Power Shares In FocusJanuary 8, 2024 | msn.comPulmatrix Inc PULMNovember 12, 2023 | morningstar.comPulmatrix Down on Q3 ResultsNovember 9, 2023 | baystreet.caPulmatrix GAAP EPS of -$1.03, revenue of $1.75MNovember 9, 2023 | msn.comPulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 9, 2023 | finance.yahoo.comAspergillosis Treatment Research Report 2023October 23, 2023 | finance.yahoo.comPulmatrix Receives Study May Proceed Letter From FDA For Phase 2 Study To Evaluate PUR3100September 19, 2023 | markets.businessinsider.comPulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute MigraineSeptember 19, 2023 | finance.yahoo.comPulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock NowSeptember 11, 2023 | msn.comPulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled ItraconazoleAugust 23, 2023 | finance.yahoo.comPulmatrix, Inc.: Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 10, 2023 | finanznachrichten.dePulmatrix GAAP EPS of -$1.04, revenue of $1.84MAugust 10, 2023 | msn.comPulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 10, 2023 | finance.yahoo.comPulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute MigraineJuly 11, 2023 | finance.yahoo.comPulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache SocietyJune 15, 2023 | finance.yahoo.com Get Pulmatrix News Delivered to You Automatically Sign up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter. Email Address PULM Media Mentions By Week PULM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PULM News Sentiment▼0.650.69▲Average Medical News Sentiment PULM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PULM Articles This Week▼40▲PULM Articles Average Week Get Pulmatrix News Delivered to You Automatically Sign up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Adverum Biotechnologies News SELLAS Life Sciences Group News IGM Biosciences News Coya Therapeutics News Acumen Pharmaceuticals News HilleVax News Vor Biopharma News MediciNova News Pyxis Oncology News DBV Technologies News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PULM) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmatrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmatrix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
